Aclarion vs YD Bio
YD Bio is the larger business, with $596,817 of revenue in fiscal 2025 against $75,730 for Aclarion (7.9 times as much). Aclarion grew faster (65.6% against 16.9%). YD Bio kept more of each dollar of sales as profit: a net margin of -1392.6% against -9551.9%.
| Latest fiscal year | AclarionACON, 2025 | YD BioYDES, 2025 |
|---|---|---|
| Revenue | $75,730 | $596,817 |
| Revenue growth | 65.6% | 16.9% |
| Net income | −$7.2m | −$8.3m |
| Operating margin | -9312.5% | -883.3% |
| Net margin | -9551.9% | -1392.6% |
| Return on equity | -104.8% | — |
| Free cash flow | −$7.2m | −$8.0m |
| Cash | $12.0m | $6.0m |
| Total debt | $0 | $6,764 |
| Debt to equity | 0.0% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 11 | — |
| Market value | $4.3m | $446m |
| Price vs our value range | — | — |
| Moat score | 8 (Weak) | — |
| Insider trades, 12 months | 11 buys, 0 sales | 3 buys, 0 sales |